MEDIFAST INC Stock: price and directors' dealings · United States · SEC (Form 4)

About MEDIFAST INC

Medifast Inc. (NYSE: MED) is a U.S.-listed health and wellness company headquartered in Baltimore, Maryland, United States. Its roots go back to 1980, and over time the business evolved from a weight-management specialist into a broader metabolic-health platform. In its latest public disclosures, Medifast describes itself as a science-backed, coach-guided lifestyle company built around structured nutrition, behavior change, and proprietary products. The company also operates a modern FDA-approved manufacturing facility in Owings Mills, Maryland, which is important operationally because it gives Medifast direct control over part of its supply chain and product quality. The core commercial engine is the OPTAVIA® brand, sold through a network of independent coaches who provide one-on-one support and accountability to clients. This model is a key differentiator versus traditional packaged-food or supplement companies: Medifast is not just selling meal replacements, it is selling an integrated system that combines product, coaching, and community. Its main product lines currently include Essential Fuelings, OPTAVIA ASCEND, and OPTAVIA ACTIVE, alongside newer protein-forward offerings designed to address evolving consumer needs. In January 2025, the company introduced OPTAVIA ASCEND, a high-protein line aimed at GLP-1 users and people trying to keep weight off. Later in 2025, Medifast announced a strategic shift toward metabolic health and launched its Metabolic Synchronization™ framework. From a competitive standpoint, Medifast operates in a crowded and fast-changing market. It faces competition from diet and lifestyle programs, digital coaching platforms, functional nutrition brands, and increasingly from the secular impact of GLP-1 obesity medications. Medifast’s advantage lies in its long operating history, its coached model, and the recurring nature of its client engagement. At the same time, the company has acknowledged pressure on its coach network and recent volume weakness, which remain central investor concerns. Geographically, Medifast remains primarily U.S.-focused, although it has some international entities and limited overseas activity. On the stock market, the company trades on the NYSE under ticker MED, in the United States. Recent headline developments include its 2025 financial results, which showed revenue of $385.8 million and a net loss for the year, while the balance sheet remained strong with substantial cash and no debt. For French-speaking investors, Medifast is best viewed as a consumer-health transition story: an established brand with a differentiated distribution model, but one that is actively repositioning itself to capture a broader metabolic-health opportunity.